The Fragility Index in Randomized Clinical Trials as a Means of Optimizing Patient Care

Area of Science:

• Clinical Research Methodology
• Evidence-Based Medicine
• Surgical Trials

Background:

• The Fragility Index (FI) quantifies the robustness of randomized clinical trial (RCT) results.
• A low FI indicates that a small change in outcomes can alter statistical significance.
• Many RCTs form the basis of clinical guidelines, yet their robustness is often unknown.

Purpose of the Study:

• To assess the robustness of RCTs in trauma and surgery using the Fragility Index.
• To highlight the importance of FI in interpreting clinical trial evidence for surgical practice.
• To advocate for the routine reporting of FI in surgical and trauma research.

Main Methods:

• Analysis of Fragility Index (FI) scores in surgical and trauma clinical trials.
• Calculation of the median FI and Fragility Quotient (FQ) for trauma trials.
• Comparison of FI scores across different medical specialties.

Main Results:

• Trauma clinical trials have a median FI of 3, indicating fragility.
• The median Fragility Quotient for trauma trials was 0.016.
• RCTs in surgery and general medicine are generally more fragile than those in cardiac disease.

Conclusions:

• Many surgical and trauma RCTs lack robustness, necessitating caution in clinical practice.
• Routine reporting of FI scores in surgical and trauma RCTs is crucial for evidence-based decision-making.
• Incorporating FI into clinical guidelines will enhance the reliability of treatment recommendations.